Does prescribing apixaban or rivaroxaban versus warfarin for patients diagnosed with atrial fibrillation save health system costs? A multivalued treatment effects analysis.
Michael SituUte I SchwarzGuangyong ZouEric McArthurRichard B KimAmit X GargSisira SarmaPublished in: The European journal of health economics : HEPAC : health economics in prevention and care (2023)
Treating AF patients with rivaroxaban and apixaban than warfarin reduces healthcare costs. OAC reimbursement policies for AF patients should consider rivaroxaban or apixaban over warfarin as the first-line treatment.
Keyphrases
- atrial fibrillation
- venous thromboembolism
- oral anticoagulants
- direct oral anticoagulants
- catheter ablation
- left atrial
- end stage renal disease
- left atrial appendage
- healthcare
- heart failure
- newly diagnosed
- chronic kidney disease
- percutaneous coronary intervention
- public health
- prognostic factors
- peritoneal dialysis
- pulmonary embolism
- social media